ZA922482B - Pharmacologically enhanced formulations - Google Patents

Pharmacologically enhanced formulations

Info

Publication number
ZA922482B
ZA922482B ZA922482A ZA922482A ZA922482B ZA 922482 B ZA922482 B ZA 922482B ZA 922482 A ZA922482 A ZA 922482A ZA 922482 A ZA922482 A ZA 922482A ZA 922482 B ZA922482 B ZA 922482B
Authority
ZA
South Africa
Prior art keywords
enhanced formulations
pharmacologically
pharmacologically enhanced
formulations
micronized
Prior art date
Application number
ZA922482A
Other languages
English (en)
Inventor
Sung J Lee
J Lee Sung
Original Assignee
Biofor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofor Ltd filed Critical Biofor Ltd
Publication of ZA922482B publication Critical patent/ZA922482B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA922482A 1991-04-05 1992-04-03 Pharmacologically enhanced formulations ZA922482B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/680,997 US5271944A (en) 1991-04-05 1991-04-05 Pharmacologically enhanced formulations

Publications (1)

Publication Number Publication Date
ZA922482B true ZA922482B (en) 1992-12-30

Family

ID=24733350

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA922482A ZA922482B (en) 1991-04-05 1992-04-03 Pharmacologically enhanced formulations

Country Status (16)

Country Link
US (1) US5271944A (de)
EP (1) EP0599914B1 (de)
AT (1) ATE155687T1 (de)
AU (1) AU1876792A (de)
CA (1) CA2052901C (de)
CH (1) CH683824A5 (de)
DE (1) DE69221150T2 (de)
DK (1) DK0599914T3 (de)
ES (1) ES2108130T3 (de)
FR (1) FR2674754B1 (de)
IE (1) IE74211B1 (de)
IT (1) ITTO920303A1 (de)
NZ (1) NZ242233A (de)
PT (1) PT100329B (de)
WO (1) WO1992017163A1 (de)
ZA (1) ZA922482B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2684298B1 (fr) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques solides a base de derives de lapiperidine substitues en 1,4.
WO1996026726A1 (en) * 1995-02-28 1996-09-06 Hoechst Marion Roussel, Inc. Pharmaceutical composition for piperidinoalkanol compounds
NZ501248A (en) * 1997-08-26 2001-06-29 Aventis Pharma Inc Pharmaceutical composition for combination of piperidinoalkanol-decongestant
EP1475093B1 (de) 2000-04-24 2006-09-06 Teva Pharmaceutical Industries Ltd. Mikronisierter zolpidem Hemitartrat
DE60122944T2 (de) * 2000-04-24 2007-04-12 Teva Pharmaceutical Industries Ltd. Mikronisiertes Zolpidem-Hemitartrat
AU2002244247B2 (en) 2001-03-01 2007-12-13 Harbor Biosciences, Inc. Use of certain steroids for treatment of blood cell deficiencies
US20060280761A1 (en) * 2002-03-11 2006-12-14 Health Plus International, Inc. Nanofluidized B-12 composition and process for treating pernicious anemia
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
BE1015641A4 (fr) * 2003-05-26 2005-07-05 Mariani Jean Paul Micronisation 70.
PT1685126E (pt) * 2003-10-16 2007-04-30 Teva Pharma Preparação de candesartan cilexetil
ES2300979T3 (es) * 2004-01-05 2008-06-16 Teva Pharmaceutical Industries Ltd. Procedimiento para la produccion de sildenafilo base y de su sal citrato.
CA2555294A1 (en) * 2004-02-11 2005-08-25 Marina Yu Etinger Candesartan cilexetil polymorphs
US20070014719A1 (en) 2004-09-29 2007-01-18 Reading Christopher L Steroid analogs and characterization and treatment methods
CN102215845A (zh) 2008-04-03 2011-10-12 哈博生物科学公司 药学试剂的固体形式
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
DE3204126A1 (de) * 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4912093A (en) * 1986-10-01 1990-03-27 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
DE3723327A1 (de) * 1987-07-15 1989-02-02 Hoechst Ag Substituierte thienoimidazol-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer, magenschutzmittel sowie als medikament gegen intestinale entzuendungen
US4892870A (en) * 1988-08-01 1990-01-09 Biofor, Ltd. Oxaza heterocycles and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
EP0599914A4 (en) 1994-08-24
DK0599914T3 (da) 1998-03-02
ITTO920303A1 (it) 1992-10-05
CA2052901C (en) 1997-12-23
EP0599914A1 (de) 1994-06-08
IE74211B1 (en) 1997-07-16
WO1992017163A1 (en) 1992-10-15
CH683824A5 (de) 1994-05-31
DE69221150T2 (de) 1998-02-26
NZ242233A (en) 1993-07-27
ES2108130T3 (es) 1997-12-16
FR2674754A1 (fr) 1992-10-09
ATE155687T1 (de) 1997-08-15
PT100329A (pt) 1993-07-30
FR2674754B1 (fr) 1994-01-14
EP0599914B1 (de) 1997-07-23
DE69221150D1 (de) 1997-09-04
AU1876792A (en) 1992-11-02
US5271944A (en) 1993-12-21
ITTO920303A0 (it) 1992-04-02
CA2052901A1 (en) 1992-10-06
IE921040A1 (en) 1992-10-07
PT100329B (pt) 1999-06-30

Similar Documents

Publication Publication Date Title
ZA922482B (en) Pharmacologically enhanced formulations
AP1637A (en) Celecoxib compositions.
MY119365A (en) Novel pharmaceutical combination
MY109512A (en) Pharmaceutical composition
CA2104461A1 (en) Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same
PT100514A (pt) 3-aminoquinuclidinas substituidas e composicoes farmaceuticas que qs contem
IE862554L (en) Pharmaceutical compositions
IL101883A0 (en) Antiviral combinations and pharmaceutical compositions containing them
MX9606502A (es) Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas.
SG46307A1 (en) New pyrazine derivatives the preparation and use thereof
CS545686A1 (en) Farmaceuticky prostredek a antihepatotoxickym pusobenim
CA2135179A1 (en) Pharmaceutical Compositions of Alkylsulphonamides 5HT1 Agonists for Rectal Administration
JPS5781409A (en) External plaster
DK0524696T3 (da) Orale præparater indeholdende dapiprazol
IT1187743B (it) Composizioni farmaceutiche a base di destrorfano per applicazione instranasale
IL70407A (en) Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine
ATE145333T1 (de) Hirudin enthaltende orale arzneimittel
DK0483320T3 (da) Farmaceutiske sammensætninger med forlænget frigivelse til peroral indgivelse og fremgangsmåde til fremstilling deraf
DE68903713D1 (de) Dextrorphansalze enthaltende orale arzneimittel.
ES2135424T3 (es) Composicion oral a base de ibuprofeno.
SE8700829L (sv) Farmaceutisk komposition
IT1249648B (it) Derivato salicilico antiinfiammatorio e antiaterosclerotico ad azione protratta
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
MX9606254A (es) Composiciones anti-inflamatorias y curativas para heridas y metodos para preparar y utilizar las mismas.
GB1081105A (en) Pharmacologically effective compositions